Navigation Links
Nature Reviews Publishes Article About Jennerex's Multi-Mechanistic Cancer Therapeutic
Date:2/10/2009

SAN FRANCISCO, Feb. 10 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Canada) a clinical-stage biopharmaceutical company, announced today that the journal, Nature Reviews Cancer, has published an article about the company's promising, targeted and armed oncolytic poxviruses, which have demonstrated encouraging clinical and preclinical data. The article, published in the January 2009 issue, was authored by David H. Kirn, M.D., president and chief executive officer of Jennerex and Visiting Professor, Department of Clinical Pharmacology, University of Oxford, and Steve H. Thorne, Assistant Professor at the Departments of Surgery and Immunology at the University of Pittsburgh Cancer Institute.

"We are honored that Nature Reviews Cancer considers oncolytic poxviruses to be such an important emerging field as to devote a full Perspectives Opinion to reviewing major recent advances. We are excited by the data that investigators have reported to date with our first-in-class cancer therapeutics. The lead product in this class, JX-594, is currently in Phase 2 testing for liver cancer and colorectal cancer. The Phase 1 intra-tumoral trial of JX-594 demonstrated objective tumor destruction in most patients, with multiple types of cancer, and we are now also studying systemic delivery of JX-594 in the clinic," stated Dr. Kirn. "Our next product from this class, JX-929, is now being evaluated in a Phase 1 clinical trial."

The article reviewed the evolution of the field of oncolytic viral therapy. First-generation agents have shown limited efficacy in the past for technical reasons elucidated by Jennerex investigators. Previous technical obstacles have provided valuable information to guide Jennerex toward a completely new class of novel, oncolytic poxviruses, combining targeted and armed approaches for treating cancer. Initial preclinical and clinical results show that prod
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Light-speed nanotech: Controlling the nature of graphene
2. Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling
3. Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice
4. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
5. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
6. MySignatureBook Certified Compliant With SAFE-BioPharma Digital Standard(TM)
7. Genetic clock makers at UC San Diego publish their timepiece in Nature
8. James L. Wittliff, Ph.D., FACB, to Present Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System at the Association for Molecular Pathology Conference, October 30
9. Natures Premium(R) Brand First Fresh Pork in North America to Carry DNA TraceBack(R) Seal of Authenticity
10. DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature
11. New yeast trick for eating favorite food: Details in Nature paper
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Boston, MA (PRWEB) , ... August 27, 2015 , ... ... the United States, ranking iLab Solutions as number 1,361 in growth for the three ... part of the top 0.1% fastest-growing privately held organizations in the country. , ...
(Date:8/27/2015)... ... 27, 2015 , ... Proove Biosciences, a commercial and ... of genetics and hypertension at the International Academy of Cardiology Annual ... Canada. The event, which boasts an extensive overview of the latest research developments ...
(Date:8/26/2015)... -- Roka Bioscience, Inc. (NASDAQ: ROKA ), a molecular ... the detection of foodborne pathogens, today announced that Paul ... Company Emerging Growth Conference on September 2 at 9:20am ... York Marriott Marquis. A live webcast ... relations section of Roka Bioscience,s website at http://rokabio.investorroom.com/ ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic company ... has received a $1.5M Phase II SBIR grant ... further develop its therapeutic agent to reduce arteriovenous ... in end stage renal disease (ESRD) patients undergoing ... Institute of Diabetes and Digestive and Kidney Diseases ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... ... , ... (Vocus) November 12, 2009 -- DuPont and Dow AgroSciences, a wholly owned subsidiary ... agreement that will enable the two companies to deliver expanded herbicide-tolerant soybean options to farmers ...
... Biotechnology, Inc. (OTC Bulletin Board: CSBR), an oncology ... accelerating the development and enhancing the value of oncology drugs, ... in oncology drug development and personalized medicine have been selected ... conference in Boston. , A poster will be ...
... ... Consulting to provide government business development services to its technology incubator companies, bringing a potential ... ... Consulting has signed a Memorandum of Understanding with the University of Florida ...
Cached Biology Technology:DuPont, Dow AgroSciences Agree to Cross License Next-Generation Soybean Herbicide Tolerant Traits 2DuPont, Dow AgroSciences Agree to Cross License Next-Generation Soybean Herbicide Tolerant Traits 3DuPont, Dow AgroSciences Agree to Cross License Next-Generation Soybean Herbicide Tolerant Traits 4Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development 2Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development 3Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development 4New Program to Bring University of Florida Incubator Companies Millions in New Contracts 2New Program to Bring University of Florida Incubator Companies Millions in New Contracts 3New Program to Bring University of Florida Incubator Companies Millions in New Contracts 4
(Date:8/20/2015)... , Aug. 20, 2015 The wearable ... that are active and healthy. However, wearable technology ... hospital environment to help improve diagnostic capabilities and ... from the Wearable Technologies Conference 2015 , ... applications for wearables in healthcare.    ...
(Date:8/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... Alliance and the EMV Migration Forum.  ... Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. direct ... promoting adoption of smart card technology. To ...
(Date:8/18/2015)... , Aug. 18, 2015  Navitas today ... contributor to the Submission Content Management webinar ... a non-profit forum. Dedicated to the Implementation of ... neutral platform for industry, vendors, health authorities, ... and work towards a standard method of ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... throughout the world and ensuring safe water supplies would do ... any other possible measure, according to an analysis released today ... water and sanitation reduces poverty in three ways. ... entrepreneurs; , Significant savings are achieved in the ...
... Researchers have discovered a mechanism for the rapid growth seen ... The tumors, which are made up of proliferating blood ... descent, with girls more frequently afflicted than boys. The ... blood-red lump on the head or facethen grow rapidly in ...
... Missouri Botanical Garden in St. Louis operates one of ... and the second largest in the western hemisphere. With ... a gigantic new aroid species from Ecuador, the ... has reached a milestone of six million specimens. ...
Cached Biology News:Providing toilets, safe water is top route to reducing world poverty: UN University 2Providing toilets, safe water is top route to reducing world poverty: UN University 3Providing toilets, safe water is top route to reducing world poverty: UN University 4Providing toilets, safe water is top route to reducing world poverty: UN University 5Researchers identify Achilles heel of common childhood tumor 2Missouri Botanical Garden mounts milestone 6 millionth herbarium specimen 2Missouri Botanical Garden mounts milestone 6 millionth herbarium specimen 3
Sterile concentration of Dithiothreitol (DTT) solution in phosphate buffer (pH 7.0). Dilute contents in one vial (10- fold) to 100 ml. For use in liquefying sputum samples....
Silica bead method is an economic method of DNA extraction from agarose...
DTT, 25g...
... overlays are commonly used in ... "DNA grade" agaroses either contain ... insect cells or lack the ... good overlays. Novagen's BacPlaque Agarose ...
Biology Products: